Ashwagandha (Withania somnifera), a cornerstone of Ayurvedic medicine, has surged in global popularity as an adaptogenic remedy marketed for everything from anxiety and fatigue to hormone balance and cancer adjunct therapy. What does the modern scientific literature actually support?
This article examines the state of empirical evidence across key domains—mental health, cognitive function, metabolic regulation, sexual health, oncologic applications, and safety—to determine whether Ashwagandha’s claims are substantiated or speculative.
Mental Health and Stress Adaptation
Among the most well-researched applications of Ashwagandha is its role in reducing stress and anxiety. A 2024 systematic review and meta-analysis of 12 randomized controlled trials (RCTs) found a significant reduction in stress and anxiety scores compared to placebo, particularly in individuals with moderate to high baseline stress [Arumugam et al., Explore, 2024]. Doses in effective studies typically ranged from 240 mg to 600 mg daily of standardized extract.
Multiple recent RCTs support these findings. Pandit et al. (2024) conducted a well-controlled trial in chronically stressed adults and reported reductions in cortisol, improvement in sleep quality, and overall stress resilience with daily Ashwagandha supplementation [Nutrients, 2024].
Verdict: Supported. Evidence quality is moderate to high; effect sizes are clinically relevant, especially in chronic stress populations.
Cognitive Enhancement and Neuroprotection
Ashwagandha’s effects on cognition have also been explored in both healthy individuals and those with mild cognitive impairment (MCI). Rai and Mishra (2025) demonstrated that 8 weeks of a Sominone-containing extract led to improvements in memory and executive function in adults with MCI [J Psychopharmacol, 2025]. The formulation was generally well-tolerated.
Animal models also provide support for neuroprotective properties. Er et al. (2025) found that Ashwagandha mitigated cognitive deficits and oxidative stress induced by sleep deprivation in rats [Biomolecules, 2025]. Similarly, withaferin derivatives have shown protective effects in dopaminergic neurons exposed to MPP+ and 6-OHDA, toxins used in Parkinson’s models [Parrales et al., ACS Chem Neurosci, 2025].
Verdict: Partially supported. Early-phase trials are promising; mechanistic plausibility is high. Larger, longer-duration human trials are needed.
Metabolic and Cardiovascular Effects
Emerging studies suggest that Ashwagandha may have modest anti-obesity and anti-inflammatory effects. In high-fat diet-induced obese mice, a complex containing Ashwagandha and Chrysanthemum zawadskii reduced adiposity and inflammatory markers [Park et al., Int J Mol Sci, 2025]. Additionally, a 2024 review detailed effects on vascular endothelium, lipid metabolism, and systemic inflammation [Wicinski et al., Nutrients, 2024].
However, human data remain limited and heterogeneous. Some improvements in lipid profiles and blood pressure have been observed in metabolic syndrome patients, but study designs vary widely.
Verdict: Tentatively supported. Animal models show consistent metabolic benefits. Human evidence is encouraging but not definitive.
Sexual Function and Testosterone
Ashwagandha has been repeatedly investigated for its effects on male sexual health, particularly testosterone levels.
The most well-known cited studies showing benefit are typically small and obfuscate the absolute differences in testosterone gain.
Verdict: The data is modestly supportive where males are subfertile or hypogonadal. The data is very weak where testosterone gain is the outcome of interest.
A well-known study [Wankhede et al., J Int Soc Sports Nutr, 2015; cited by 335] found that 29 young men taking ashwagandha root (300 mg twice a day over 8 weeks) had a bigger rise in testosterone than 28 young men on placebo. However, this did not lead to a clear difference in final testosterone levels between the groups. This may be due to big measurement uncertainty between individuals and a very small overall effect. The authors also did not show a clear change in testosterone before and after ashwagandha use - so it's unclear if there was any real effect at all.
One study [Ahmad et al., Fertil Steril, 2010; cited by 307] examining infertility did find an increase in testosterone - for a small group of men, testosterone increased by about 1ng/mL (100ng/dL, 3.46nmol/L). They were prescribed ashwagandha root powder at 5g per day orally for 3 months with milk.
In animal models, the mechanism appears to involve nitric oxide/cGMP/PDE5α signaling pathways, modulating neurotransmitter levels and arousal [Yadav & Mishra, J Ethnopharmacol, 2024].
A crossover RCT in aging overweight males found significant increases in testosterone, vitality, and strength parameters after 8 weeks of Ashwagandha root extract supplementation [Lopresti et al., Am J Mens Health, 2019].
Verdict: Some data supportive of use in subfertile or hypogonadal males. Mechanistic and clinical coherence is plausible in this subgroup.
Oncologic Applications
Claims regarding Ashwagandha’s anticancer properties require caution. While Elzayat et al. (2025) showed in vitro synergy between Ashwagandha extract and doxorubicin in MCF7 breast cancer cells, this preclinical result lacks translation into human efficacy [APJCP, 2025].
Withaferin A, a key constituent, demonstrates anti-proliferative and apoptotic effects via NF-κB and oxidative stress pathways in cell models [Nisar et al., Naunyn-Schmiedebergs Arch Pharmacol, 2025].
Verdict: Not yet clinically supported. Promising in vitro and mechanistic data—but absence of in vivo or human data limits clinical recommendation.
Safety, Drug Interactions, and Regulatory Gaps
Ashwagandha is generally considered safe in healthy adults when used short-term. However, risks include thyroid hormone elevation, mild GI upset, and sedation. Case reports have raised concern for rare instances of hepatotoxicity and adrenal suppression [Patel et al., Br J Hosp Med, 2024].
A 2025 study showed significant interactions between Ashwagandha and cytochrome P450 enzymes, implying risk of altered metabolism of co-administered drugs [McDonald et al., J Diet Suppl, 2025].
Standardization is also problematic. Zellner et al. (2025) demonstrated wide variation in withanolide content across commercial formulations, some of which lacked key constituents entirely [Electrophoresis, 2025].
Verdict: Use with caution. Drug interactions and endocrine effects require further pharmacovigilance and tighter regulation.
Conclusion
Ashwagandha is not a panacea. It offers possible benefit in stress reduction, and potentially cognitive and metabolic enhancement, particularly when standardized extracts are used in appropriately selected individuals. However, its oncologic applications remain preliminary, and safety in polypharmacy or endocrine-sensitive individuals warrants attention.
Further large-scale, independently funded trials with biomarker endpoints are essential to move Ashwagandha from complementary folklore into integrated clinical practice.
Other Online Sources
Key References
- Wankhede et al. J Int Soc Sports Nutr, 2015
- Arumugam V et al. Explore, 2024
- Pandit S et al. Nutrients, 2024
- Rai HP & Mishra DN. J Psychopharmacol, 2025
- Parrales V et al. ACS Chem Neurosci, 2025
- McDonald KL et al. J Diet Suppl, 2025
- Lopresti AL et al. Am J Mens Health, 2019
- Nisar MF et al. Naunyn-Schmiedebergs Arch Pharmacol, 2025
- Zellner L et al. Electrophoresis, 2025
- Wicinski M et al. Nutrients, 2024
- Smith SJ et al. Adv Nutr, 2021
- Elzayat EM et al. APJCP, 2025
- Patel M et al. Br J Hosp Med, 2024